BA
IBB icon

Bristlecone Advisors’s iShares Biotechnology ETF IBB Stock Holding History

Bristlecone Advisors’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-786
Closed -$99.4K – 254
2025
Q2 		$99.4K Sell
786
-137
-15% -$16.8K 0.01% 235
2025
Q1 		$118K Hold
923
– – 0.01% 286
2024
Q4 		$122K Hold
923
– – 0.01% 287
2024
Q3 		$134K Hold
923
– – 0.01% 288
2024
Q2 		$127K Buy
+923
New +$123K 0.01% 284
2023
Q2 		– Sell
-488
Closed -$63K – 299
2023
Q1 		$63K Buy
+488
New +$63.9K 0.01% 293
2017
Q4 		– Sell
-270
Closed -$30K – 198
2017
Q3 		$30K Buy
+270
New +$28.9K 0.01% 226

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
CB
Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Bristlecone Advisors's IBB Position: Q3 2025 in Review

Bristlecone Advisors sold out of iShares Biotechnology ETF (IBB) in Q3 2025, closing a stake of 786 shares — an estimated $99.4K sold.

Bristlecone Advisors first reported a position in IBB in Q3 2017 and held it in 7 quarters. The position peaked at $134K in Q3 2024. 803 funds tracked by Wall St. Rank hold IBB as of Q3 2025.

  • Bristlecone Advisors reported no remaining iShares Biotechnology ETF position as of Q3 2025 after selling out during the quarter.
  • Bristlecone Advisors sold 786 iShares Biotechnology ETF shares in Q3 2025, an estimated $99.4K.
  • Bristlecone Advisors first reported a position in iShares Biotechnology ETF in Q3 2017 and held it in 7 quarters.
  • Bristlecone Advisors's iShares Biotechnology ETF position peaked at $134K in Q3 2024.
  • 803 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q3 2025.

Based on Bristlecone Advisors's 13F filing for Q3 2025, filed 24 Oct 2025.